about
The role of drug transporters in the kidney: lessons from tenofovirProteinuria in paediatric patients with human immunodeficiency virus infectionThe other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapyTenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsLiver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infectionRenal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Renal disease in HIV-infected individualsNephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in ThailandSmoking and renal function in people living with human immunodeficiency virus: a Danish nationwide cohort study.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.Effect of GSTM1-Polymorphism on Disease Progression and Oxidative Stress in HIV Infection: Modulation by HIV/HCV Co-Infection and Alcohol Consumption.Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.Impaired Urine Dilution Capability in HIV Stable Patients.Antiviral drugs and the treatment of hepatitis C.HIV therapies and the kidney: some good, some not so good?Update on tenofovir toxicity in the kidney.Emerging antiretroviral drugs.Predictors of HIV-associated nephropathy.The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy.Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.Diagnostic challenges of kidney diseases in HIV-infected patients.Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection.Tenofovir nephrotoxicity: 2011 update.Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney.HIV and mitochondria: more than just drug toxicity.Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.Nonclinical Safety Profile of BMS-986001, a Nucleoside Transcriptase Inhibitor for Combination Retroviral Therapy.Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
P2860
Q26866489-68C0F90C-4250-48B4-92A3-55AC581C4F27Q27009315-35A39544-1152-45BB-A8CB-E8AC66B14A4AQ27027887-907D0D8A-BE00-44A0-A774-A4073E8AC59EQ33845879-7CE4DC27-4953-4F04-8246-372D2796ED06Q34730950-13427C85-6DAB-4EFE-8429-FDD89EC120E3Q34978897-B1699DAB-6168-4C7C-B991-B998325A726AQ35043048-D3AF488E-84E6-45B4-B3DD-DB37B1E5EBECQ35091365-8264B6D5-382C-4879-84AC-1A6A4DF69807Q35170350-A0924760-130C-437B-A760-F04F5F8C3F27Q35698442-7AB4CB50-9635-48B0-B881-374246CFA90EQ35864595-21635EB4-30AE-4C2C-AA04-0124A016E341Q36024738-CA732F02-37C6-4FF7-B36C-EC9A8267EEA6Q36097686-76178907-1F3C-46BF-8DAC-662986DE63DBQ36993353-889CED44-7A86-4789-8867-2ACB2F283062Q37238911-F8538F77-B958-405B-A3B8-518AE9512C91Q37460405-65124370-3FF7-4652-BBA2-EBBBED928CD5Q37641171-6F4957E1-5A67-4368-BE35-85FFDE4E9205Q37706095-F86C9F0C-E199-45CF-8EA3-813AEB5A92BDQ37987057-A809C530-20B5-46D6-A2DF-98D3FD6EF2FBQ37988776-E84C7A04-BB49-4429-96D6-CAB84DB734FDQ38033446-A195CC22-ABA0-4B04-9ECD-269419CA1983Q38167382-7943617E-56E3-4192-8CBB-5CEC84774AF0Q38198151-F8C347FE-4950-4AFB-8310-3076CBC4C947Q38520954-7DE643AC-532C-4E6D-A1C6-5D5CF2707816Q38661064-CF1115BB-794A-4905-A86C-3A8610E1AB6DQ39118603-356D28E5-78F0-497C-B540-610D9CB972BCQ39196660-A7173102-CF38-478C-B0CC-B4CFB3877528Q39611116-D1B22567-8A37-490B-BB95-A5D3DE859625Q39713984-6BB5D54A-E987-471F-8137-B7BDC22F0567Q40051440-61FEFD6F-74E8-497C-9FBF-9FA97C8818B7Q40541589-C0A8AA38-0A69-4AD5-9D0D-16A12A46BFBAQ40785692-A4C220D0-2DD6-41FE-98F3-2AC8BE9D0DB8Q41204065-120FD3D5-6084-4413-AF3E-B331C0CB9EE4Q41507823-3B22D6BD-6A26-4F9C-BDC2-C8DC978BE4E9Q42254390-CF354C43-9BF5-48B3-9627-DB0938565602Q42588985-28906357-2B9C-4299-AF99-17A2B7C2C4E1Q43179450-A0FD5AD0-0AFE-43CC-B3D3-4297BAB3F840Q43493641-4A95555C-40E9-4D8A-8914-208426817A1CQ44003033-38256698-0ACC-4F65-91ED-8BBB6CE95334Q45334368-83EAE06D-F1E1-483B-9007-D2E8B4ADEF7B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal toxicity associated with tenofovir use.
@en
Renal toxicity associated with tenofovir use.
@nl
type
label
Renal toxicity associated with tenofovir use.
@en
Renal toxicity associated with tenofovir use.
@nl
prefLabel
Renal toxicity associated with tenofovir use.
@en
Renal toxicity associated with tenofovir use.
@nl
P2093
P2860
P1476
Renal toxicity associated with tenofovir use.
@en
P2093
Elena Alvarez
Pablo Labarga
Sonia Rodriguez-Nóvoa
P2860
P304
P356
10.1517/14740331003627458
P407
P577
2010-07-01T00:00:00Z